Oxford, UK, 27 February 2006 - VASTox (AIM: VOX), a leading chemical genomics company, today announces it has successfully raised £10.45 million in a placing of New Ordinary Shares to institutional investors. The new funds will be used by the Company to accelerate the development of its lead therapeutic programme in Duchenne muscular dystrophy (DMD), for which it announced promising preclinical results earlier this year. The Placing has been fully underwritten by Evolution Securities Limited.
